Onco Actu du 2 juin 2016

	2. Etiologie
Study Links Periodontal Disease Bacteria to Pancreatic Cancer Risk [JAMA] “Inflammation is related to cancer. The bacteria could be causing inflammation in the pancreas: that’s one theory,” Ahn said. “But maybe the bacteria in the mouth is just a marker for the susceptibility of the body to inflammation.”
	2.7 Etiologie - Obésité
Prostate cancer: Four inches extra on a man's waistline increases deadly disease risk by a fifth [The Telegraph] The 14-year-study, which spanned eight countries, found that overall, an extra four inches on the waist was associated with a 13 per cent increased risk of prostate cancer – and an 18 per cent rise in fatal disease.
	4.10 Dép., diag. & prono. - FDA, EMA, NICE,...
FDA approves first blood test to detect gene mutation associated with non-small cell lung cancer [FDA] With the cobas EGFR Mutation Test v2, the presence of specific NSCLC mutations [exon 19 deletion or exon 21 (L858R) substitution mutations] detected in patients’ blood samples aids in selecting those who may benefit from treatment with Tarceva.
Roche's liquid biopsy test gets U.S. approval [Reuters] Cobas EGFR Mutation Test v2, a blood-based companion diagnostic for cancer drug Tarceva, is the first FDA-approved genetic test that can detect epidermal growth factor receptor (EGFR) gene mutations which are present in about 10-20 percent of NSCLC patients.
	5. Traitements
Controlling Cancer with Evolution [The Last Word On Nothing] Spath and the other study participants receive Zytiga, a therapy that stops the production of testosterone. Most men with prostate cancer take Zytiga continuously, but in this study the subjects start and stop the drug depending on their tumor’s response.
	5.12 Immunothérapies
Universal cancer vaccine on horizon after genetic breakthrough [The Telegraph] “The approach introduced here may be regarded as a universally applicable novel vaccine class for cancer immunotherapy.”
'Trojan horse' cancer-fighting injection sparks hope in human trials [The Guardian] Made in the lab, the Trojan horse is composed of nanoparticles containing cancer RNA – a form of genetic coding – enclosed by a fatty acid membrane. The particles are injected into patients to simulate a viral infection, and infiltrate specialised immune cells. These dendritic cells decode the RNA embedded in the nanoparticles – triggering, in turn, the production of cancer antigens.
	5.2 Pharma
Facing rival drugs, Novartis gets win with Afinitor in Europe [Reuters] Consensus forecasts have pointed to Afinitor sales peaking at more than $2 billion in 2018, according to Thomson Reuters Cortellis.
	5.3 Traitements - FDA, EMA,...
Kite Pharma Granted Access to Priority Medicines (PRIME) Regulatory Support for KTE-C19 in the Treatment of Chemorefractory Diffuse Large B-Cell Lymphoma (DLBCL) [KITE] KTE-C19 is an investigational therapy in which a patient's T-cells are genetically modified to express a chimeric antigen receptor (CAR) designed to target the antigen CD19, a protein expressed on the cell surface of B-cell lymphomas and leukemias.
EMA Accepts Four Products to Priority Medicines Scheme [RAPS] Like the US Food and Drug Administration's (FDA) breakthrough therapy program, PRIME aims to streamline the development of promising new therapies through earlier scientific advice and increased engagement between EMA and sponsors in order to facilitate an accelerated assessment of the product.
First statistics on PRIME are released [EMA] EMA is making available detailed information on the applications that have been granted or denied access to PRIME, including statistics on the type of applicants, the therapeutic areas represented and the data supporting the applications.
	5.3.4 Traitements - AMM (FDA, EMA)
Novartis drug Afinitor® receives EU approval to treat certain types of advanced gastrointestinal (GI) and lung neuroendocrine tumors (NET [Novartis] The EU approval of Afinitor was based on efficacy and safety data from a pivotal Phase III study (RADIANT-4) evaluating Afinitor versus placebo in patients with advanced, progressive, well-differentiated nonfunctional NET of GI or lung origin.
	5.4 Traitements - Economie
ASCO Value Framework Update [ASCO] In addition, the framework will continue to focus on cancer drugs, rather than other interventions. As some commenters noted, the cost of drugs is only one component of overall cancer care costs. But evidence shows that drug costs are the most rapidly rising component of cancer care and among patients’ biggest concerns—in large part because they pay a significant share of these costs through co-pays.
How can patients get their money's worth from cancer meds? ASCO revamps 'value' tool to help decide [FiercePharma] The new framework also adds points for treatments that help control cancer in the long term for a “significant portion” of patients. It considers the full range of side effects linked to each treatment, rather than focusing on the most serious, as the first proposal did.
NICE asks company to put leukaemia drug forward for new Cancer Drugs Fund [NICE] If the company puts forward a proposal that is accepted by NICE and NHS England, conditional funding will be made available for ibrutinib in the CDF while more evidence is gathered to show how well it works.
For some drugs, perhaps we should pay more [The Incidental Economist] You hear politicians calling for lower drug prices. But you may not be hearing about how low prices contribute to drug shortages. The drugs most prone to shortage are generic injectable ones, administered to patients in the hospital or a doctor’s office. They include anticancer agents, heart attack medications and anesthetics, many used in life-threatening, emergency situations.
Global cancer drug spending to exceed $150 billion by 2020: IMS report [Reuters] That represents an annual global growth rate for oncology drug spending of 7.5 percent to 10.5 percent through 2020, up from last year's IMS forecast of 6 percent to 8 percent growth through 2018.
	6. Lutte contre les cancers
What It Takes to Get a Cancer Doctor to Say ‘Cured’ [Bloomberg] “We’re early in the journey,” said David Reese, senior vice president of translational sciences at biotechnology firm Amgen Inc. “Why is it still a minority of patients that have these extraordinary responses? That’s the hard work that needs to be done now.”
Well: How Much Do You Want to Know About Your Cancer? [NY Times] One of the biggest problems we face is that we often can’t figure out what our patients would like to know about their prognosis. Even when we ask.
	6.10 Politiques
The Cancer Moonshot: A perspective in 4 graphs [HealthNewsReview] It has been almost six months since the “Cancer Moonshot” initiative was proposed by President Obama. Here are some reflections on all of the hype surrounding the initiative and some data that, in my opinion, have not gotten the attention they deserve.
	6.5 Médecines alternatives
The quackery that is “naturopathic oncology” [Respectful Insolence] Efficacy should be established first, and then utilization and cost are worth studying. In the world of naturopathic oncology, it doesn’t matter if the treatments being studied work or not.
	6.6 Publications
What does scientific reproducibility mean, anyway? [STAT] Even when scientists think they know what’s required to reproduce a finding, they often are mistaken. Take, for example, studies that gather huge amounts of data, such as those on gene activity.
What does "reproducibility" mean? New paper seeks to standardize the lexicon [Retraction Watch] What is the difference between “reproducible” and “replicable”? And how does each relate to results that are “generalizable” and “robust”? Researchers are using these terms interchangeably, creating confusion over what exactly is needed to confirm a scientific result, argues a new paper published today in Science Translational Medicine.
	6.7 DMP, Big Data & applis
Flatiron Health Unveils the Next Version of its Oncology Software Suite: OncoCloud [Flatiron] In addition to key updates to its core products, the company added a new solution to enable its clients to participate in value-based care initiatives like the Oncology Care Model (OCM). Together, the suite is the industry’s most comprehensive cloud-based software offering for community oncology practices
	6.8 Communication
The Big C and Me: a humane and responsible look at ordinary people living with cancer: review [The Telegraph] Sometimes in documentaries the camera goes somewhere private and viewers become voyeurs. That sense was inescapable in a tender, painful moment of family intimacy during The Big C & Me (BBC One), a calm and humane new series reporting on the lives of ordinary people living with cancer.